63610-09-3
63610-09-3 结构式
基本信息
2-氨基-2-(羟甲基)丙烷-1,3-二醇 半(2,2'-((2-氯-5-氰基-1,3-亚苯基)双(氮烷二基))双(2-氧代乙酸盐) )
AloMide
U-42585-E
LodoxaMide troMetaMol
Lodoxamidetromethamine
Lodoxamide Tromethamide
LodoxaMide troMethaMineon
LodoxaMide troMethaMine salt
Lodoxamide tromethamine (U 42585 E)
2-Amino-2-(hydroxymethyl)propane-1,3-diol hemi(2,2'-((2-chloro-5-cyano-1,3-phenylene)bis(azanediyl))bis(2-oxoacetate))
常见问题列表
lodoxamide inhibits compound 48/80-induced histamine release and ionophore-induced 45 Ca influx with associated histamine release in purified rat peritoneal mast cells.
Lodoxamide has been demonstrated to have cromolyn-like activity when studied in the rat peritoneal mast cell assay (PCA) model3 and in Ascaris antigen-sensitized rhesus monkeys. When given intravenously, orally, or intrabronchially by aerosol, lodoxamide significantly inhibits the increased respiratory frequency and decreased tidal volume induced by antigen challenge in Ascaris-sensitized. anesthetized rhesus monkeys. Addition of lodoxamide tromethamine to Euro-Collins or University of Wisconsin solution results in a marked decrease in lung reperfusion injury as demonstrated by increased oxygenation, decreased microvascular permeability, and increased compliance. Patients treated with lodoxamide tromethamine demonstrate an improvement in daytime breathing difficulty, cough, sputum production, and sleep.